this whole wave of articles saying “the model is not the product” as if that’s a new idea 2019 (pre-genai)…
then again in 2023 (post-genai)… stay ahead of the curve with @airstreetpress
@nathanbenaich
-
Repetitive ‘model is not product’ articles since 2019
By
–
-
AGI is bottlenecked by integrations, says Nathan Benaich
By
–
agi is bottlenecked by integrations. x.com/gdb/status/206…
-
Claude Code Search critique: poor for older code retrieval
By
–
claude code search is not very good – esp for anything older than a few weeks
-
AI as driver of growth: UK and Europe need full speed ahead
By
–
good takes – ai is clearly the driver of growth, which the uk and europe lack, so i don’t quite see any other way to go than full speed on ai, ever fuller than we could have before – to make up for a decade+ of being asleep at the wheel. i’d also bring the public in by doing a
-
ChatGPT record and replay unavailable in Europe
By
–
gdammit, chatgpt record and replay not avail in europa
-
Europe cannot rent its way to AI sovereignty
By
–
Europe cannot rent its way to AI sovereignty. TLDR, here is my opinion that I shared this week with leaders of cutting-edge AI labs. When Washington can disable a model overnight, the question is not whether AI is
-
Intense week for AI in biology: record deal and scaling
By
–
it's been a huge few weeks for ai in bio: a $2.25b @profluentbio x @elilillyandco deal on ai-designed gene editors, verve's base-editing data, new scaling results on protein models from @czbiohub, @isomorphiclabs' haul.@thisismadani and i recorded a pod diving into all of it… pic.twitter.com/QNAuGmsjQW
— Nathan Benaich (@nathanbenaich) 18 juin 2026It has been intense weeks for AI in biology: a $2.25 billion deal between @profluentbio and @elilillyandco on gene editors designed by AI, Verve's base editing data, new scaling results on protein models from @czbiohub, the
-
LabGeni partners with LG Chem for AI-driven tumor-targeting antibodies
By
–
more @airstreet news! @labgeni_us partners with korea's largest chemicals company lg chem to develop tumor-targeting antibodies using their ai-driven platform
-
Exponential accumulation of AI capabilities and need for open weights
By
–
We believe that capabilities will most likely continue to accumulate exponentially. We believe that a world where a handful of companies provide all AI is worse than one where many can develop it. We believe that open weights and the